Literature DB >> 15153654

Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search.

Takeshi Hiramoto1, Yosuke Nonaka, Kazuko Inoue, Takefumi Yamamoto, Mariko Omatsu-Kanbe, Hiroshi Matsuura, Keigo Gohda, Norihisa Fujita.   

Abstract

G protein-coupled receptors (GPCRs) are distributed widely throughout the human body, and nearly 50% of current medicines act on a GPCR. GPCRs are considered to consist of seven transmembrane alpha-helices that form an alpha-helical bundle in which agonists and antagonists bind. A 3D structure of the target GPCR is indispensable for designing novel medicines acting on a GPCR. We have previously constructed the 3D structure of human P2Y(1) (hP2Y(1)) receptor, a GPCR, by homology modeling with the 3D structure of bovine rhodopsin as a template. In the present study, we have employed an in silico screening for compounds that could bind to the hP2Y(1)-receptor model using AutoDock 3.0. We selected 21 of the 30 top-ranked compounds, and by measuring intracellular Ca(2+) concentration, we identified 12 compounds that activated or blocked the hP2Y(1) receptor stably expressed in recombinant CHO cells. 5-Phosphoribosyl-1-pyrophosphate (PRPP) was found to activate the hP2Y(1) receptor with a low ED(50) value of 15 nM. The Ca(2+) assays showed it had no significant effect on P2Y(2), P2Y(6), or P2X(2) receptors, but acted as a weak agonist on the P2Y(12) receptor. This is the first study to rationally identify surrogate ligands for the P2Y-receptor family.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153654     DOI: 10.1254/jphs.95.81

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  3 in total

1.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

Review 2.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2.

Authors:  Titilayo O Johnson; Abayomi Emmanuel Adegboyega; Opeyemi Iwaloye; Omokehinde Abiodun Eseola; Winfried Plass; Boluwatife Afolabi; Damilare Rotimi; Eman I Ahmed; Ashraf Albrakati; Gaber E Batiha; Oluyomi Stephen Adeyemi
Journal:  J Pharmacol Sci       Date:  2021-05-23       Impact factor: 3.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.